Aim: The present investigation endeavors the importance of natural polymers for the sustained oral drug delivery. In an attempt to weigh up the efficiency of natural polymers in sustained oral delivery, an antidepressant venlafaxine hydrochloride, a highly water-soluble drug was selected as a challenging model. Materials and Methods: Different formulations (F1-F12) were prepared using drug, xanthan gum (XG), guar gum (GG) at 1:1, 1:2, and 1:3 ratios, and different polymer blends of chitosan, XG, and GG at 1:1, 1:4, and 4:1 ratios. Multiparticulates (granules) were prepared using wet granulation method and then were filled into empty hard gelatin capsules. The prepared multiparticulate drug delivery systems (MDDS) were characterized for drug-excipient compatibility study, physical evaluation, and in vitro drug release. Results and Discussions: Fourier-transform infrared spectroscopy study confirmed the absence of chemical interactions between drug and polymers. Differential scanning calorimetry analysis indicated the uniform dispersion of drug in the matrix. The physical and flow properties of the granules and MDDS were evaluated and found to be within the acceptable limits. The in vitro drug release study of the optimized formulation (F8) sustains the release of drug to 85.3% at the end of 20 h, while Venlor XR sustains the release of drug to 97.35% at the end of 12 h. Kinetic analysis of dissolution data indicated that the drug release follows first-order kinetics through Quasi-Fickian diffusion. Conclusion: It can be concluded from the study that the prepared MDDS using polymer blend of chitosan with XG at 1:4 ratio are the versatile release retardant material, which could release the drug for 20 h.
INTRODUCTION

B
y designing a dosage form with aptitude to release its contents at an unremitting and controlled rate for a long extent of instance, constant plasma drug levels can be attained. [1] Such dosage forms which can accurately control the drug release rates and/or target the drug to specific body site will remain high demand in the future. Among various controlled release dosage systems, multiparticulate drug delivery systems (MDDS) have been developed in recent years to modify drug release and for improvement of bioavailability or stability and to target drug to specific sites. [2, 3] MDDS consists of the variety of small discrete units that exhibit different characteristics. Simultaneously, these characteristic units such as granules, beads, microspheres, pellets, spheroids, and Minitab provide the overall desired controlled release of the dose. [4] MDDS provide the advantage of more uniform spreading throughout the gastrointestinal tract and invariably maximize drug absorption, reduce peak plasma fluctuation, and minimize the potential side effects without lowering drug bioavailability. [5, 6] A distinction can be made between monolithic and multiparticulate controlled release formulation is relating to it's in vivo behavior because the subunits spread into the gastrointestinal tract as soon as the hard gelatin capsules or the tablet disintegrates, hence, drug release occurs over a large area avoiding high local drug concentrations. [7] RESEARCH ARTICLE Drug substances with high water solubility and short halflife (elimination half-life 2-3 h) get readily absorbed and eliminated, thus requiring frequent administration. This may lead to decrease in patient compliance and increase chances of side effects due to dose dumping. [8] Venlafaxine hydrochloride, a novel third-generation antidepressant and, is referred to as a serotonin, norepinephrine-dopamine reuptake inhibitor. [9] Due to high water solubility, first pass metabolism, low bioavailability, and short half-life extended release MDDS of venlafaxine hydrochloride became the key requirement to eliminate multiple daily dosages and minimize side effects. [10] The use of biopolymers in controlled release applications has increased in recent years due to their efficient delivery and in extending the release time of short-lived drugs over those of the conventional type dosage forms. [11] Due to the major advantages, polymer blends offer as coating materials for controlled drug delivery systems, [12] it can be expected by the use of polymers such as xanthan gum (XG) and guar gum (GG) with chitosan. Such blended polymers protect the release of the drugs in the acidic environment and will swell and get hydrated on reaching the intestine when in contact with the alkaline medium and the release the drug slower over a long period.
[13]
The aim of the present study was obtaining of MDDS using natural polymers for retarding release of the drug. In these regards, chitosan is selected as it has been used in pharmaceutical formulations as a release controlling agent, due to its appealing properties such as biocompatibility, biodegradability, low toxicity, and relatively low production cost from abundant natural sources. [14] Chitosan is a deacetylated derivative of chitin, which is a naturally occurring polysaccharide comprising copolymers of glucosamine and N-acetylglucosamine. The cationic amino groups on the C2 position of the repeating glucopyranose units of chitosan can interact electrostatically with the anionic groups (usually carboxylic acid groups) of other polyions to form polyelectrolyte complexes. [15] Although polyelectrolyte complex as the matrix of controlled release has some obvious advantages such as increasing the controlledrelease ability and reducing the pH dependence, preparation of polyelectrolyte complex was a lengthy process. As an alternative for this lengthy process, here, we propose in situ chitosan-XG and chitosan-GG polyelectrolyte complexation as a tool for controlling drug release. [16] Therefore, the main objectives of this study are (1) to develop MDDS of venlafaxine hydrochloride using natural polymers as release retardant and (2) to evaluate the release characteristics and mechanisms of drug release.
MATERIALS AND METHODS
Materials
Venlafaxine hydrochloride was purchased from Hermes chemical company Pvt., Ltd., Hyderabad, chitosan, XG, and GG from Sigma-Aldrich, Bengaluru. Dibasic calcium chloride, chitosan, alcohol, and PVP K-90 from Sisco Research Laboratories Pvt., Ltd. (SRL), Hyderabad, India, were used. All other materials were of analytical or reagent grade.
Drug-excipient compatibility study
Fourier-transform infrared (FTIR) spectroscopy FTIR spectra of venlafaxine hydrochloride, physical mixtures of excipients of optimized formulation (placebo), and the optimized formulation were recorded on FTIR spectrometer (Model ALPHA T, Bruker). 2 mg sample was mixed with 200 mg potassium bromide (KBr). These mixtures were grinded into fine powder, and then compressed into KBr disc using a hydraulic press. Each KBr disc was scanned over a wave number region of 500-4000 cm −1 and the resolution was 4 cm −1
. The characteristic bands were recorded for all samples. FTIR analysis was used to analyze the stability of drug within the polymeric material. [17] 
Thermal analysis
The thermal analysis of pure venlafaxine hydrochloride, physical mixture of optimized formulation was recorded using a differential scanning calorimetry (DSC) (Model-SDT Q600, USA) by heating from 40 to 600°C at a heating rate of 10°C/min under nitrogen atmosphere (flow rate, 20 ml/min).
[9]
Preparation of granules of venlafaxine hydrochloride
In the present work, MDDS of venlafaxine hydrochloride were prepared in two stages. In the first stage, granules of different formulations were prepared by wet granulation method. In the second stage, prepared granules of all formulations equivalent to 75 mg were weighed and filled into hard gelatin capsule.
A total of 12 formulations were tried from F1 to F12 and their composition was shown in Table 1 . In each formulation, specified quantities of venlafaxine hydrochloride, dibasic calcium chloride, XG, GG, chitosan, and PVP K-90 were weighed and passed through sieve #60.
In the first group, the drug was mixed with single release retardant polymer, i.e., XG or GG in a drug to polymer ratio (D:P) of 1:1, 1:2, and 1:2.8 along with dibasic calcium chloride, PVP K-90 and labeled as F1, F2, F3, F4, F5, and F6, respectively. In the second group, the drug was mixed with polymer blend of chitosan (CH) and (XG/GG) at 1:1, 1:4, and 4:1 ratios along with PVP K-90 and labeled F7, F8, F9, F10, F11, and F12, respectively. All the above formulations (F1-F12) were mixed well in a mortar using a spatula. The multiparticulates (granules) were prepared by utilizing alcohol into damp mass. Then, the wet mass was passed through sieve #16. The wet granules were air dried for 2 h and then passed through sieve #22.
Evaluation of physical and flow properties of granules
Prepared granules were evaluated for flow properties and particle size distribution.
Flow properties
The flow properties of the prepared granules were determined by angle of repose θ, using fixed funnel method. The bulk and tapped densities for the prepared granules were determined by tapping method and the compressibility index using the data. [18] Particle size distribution
To determine the particle size distribution of prepared granules containing venlafaxine hydrochloride, standard sieve method was used. Mechanical sifter with sieves between apertures 355 and 2000 µm was used using all the amount of blend prepared. The fraction collected on each of the sieves was calculated by the percentage value.
Preparation of MDDS
All prepared granules of 12 formulations are accurately weighed (equivalent to 75 mg of drug) were filled in size "1" hard gelatin capsules using hand-operated capsule filling machine.
Evaluation of physicochemical properties of MDDS
Filled capsules of different formulations (F1-F12) were evaluated for weight variation, disintegration time, drug content, and in vitro drug release.
Weight variation
Individual weights of 20 capsules were taken and the average weight was calculated using the following formula:
Weight of capsule Average weight of capsules Weight var iation Average weight of capsules
Weight variation should not be more than 5%. [19] 
Disintegration time
One capsule was placed in each of six tubes of disintegration assembly (Electrolab and Model: ED-2L) and was suspended in water. Discs were added to each tube, temperature was maintained at 37 ± 2°C and assembly was operated for 30 min as per B.P. [20] Drug content A total of 10 capsules were selected and the contents were removed. From this, an accurately weighed amount of sample equivalent to 100 mg of venlafaxine hydrochloride was taken in a volumetric flask (100 ml). The content was dissolved in water and the volume was made up to 100 ml. This solution was filtered through Whatman filter paper No.41. The solution was suitably diluted and the drug content was estimated by measuring the absorbance at 254 nm in ultraviolet-visible spectrophotometer (Shimadzu). [21] In vitro drug release study
In vitro drug release studies for all formulations as well as commercial available product (Venlor XR) were carried out using dissolution test apparatus USP Type-II (Electrolab and Model: ESP-84) at 50 rpm. The dissolution test was performed using 900 ml of distilled water and the temperature was maintained at 37°C ± 0.5°C. Aliquots of 5 ml were withdrawn at predetermined time intervals and an equivalent amount of fresh dissolution fluid equilibrated at the same temperature was replaced. Aliquots withdrawn were diluted up to 50 ml with buffer, filtered and analyzed by measuring the absorbance at 278 nm.
[15]
Kinetic treatment of dissolution data
To describe the kinetics of drug release, zero-order (Qt= Q0 + K0t), first-order (In Qt = In Q0 + K1t), Higuchi (Qt =KHt
), and Korsmeyer-Peppas (Qt/Q∞= Kt n ) models were fitted to the dissolution data of selected formulations (F7, F8, F9, F11, and Venlor XR), using linear regression analysis. A value of n = 0.5 indicates Case I (Fickian) diffusion, 0.5< n< 1 anomalous (NonFickian), n = 1 Case II transport, and n > 1 super Case II transport. [22] RESULTS AND DISCUSSIONS Drug-excipient compatibility study
FTIR spectroscopy
The FTIR spectra of drug, venlafaxine hydrochloride showed characteristic stretching bands at 3367.38, 3324.83,1611.52, 1512.08, and 1179.25 cm −1 corresponding to functional groups O-H, C=H,C-O, and C-N in the below Figure 1a 
Thermal analysis
The DSC analysis of venlafaxine hydrochloride and physical mixture of optimized formulation was carried out and the results Figure 2b ], disappearance of the endothermic peak at 217°C suggests that the drug is uniformly dispersed in chitosan and XG matrix.
Physical and flow properties of granules
Prepared granules of different formulations from F1to F12 were evaluated and shown in Table 2 . The angle of repose value for granules from F1 to F12 was found to be in the range of 24 and 31.62°.The Carr's index of granules from F1 to F12 was found to be in the range of 14.8-19.9. The bulk density of the prepared granules was in the range of 0.2490-0.3157. The bulk density, Carr's index, and angle of repose values of all prepared granules indicated that they possess average to good flow properties. Particle size distribution of all the prepared granules (F1-F12) was uniform and found to be 245-276 µm.
Physicochemical properties of MDDS
The average weight of all formulations (F1-F12) was ranged from 391.4 to 398.6 mg. Disintegration time of all formulations (F1-F12) was found to be 24.59-29.92. The percent drug content of all formulations (F1-F12) was found to be 95.3-99.4 and was within the acceptable limits of I.P. All these values were depicted in Table 3 .
In vitro drug release study
In vitro dissolution studies were performed in distilled water and the results were depicted in Table 4 . The drug release from formulations F1-F6 made with XG or GG as a single release retardant material was shown in Figure 3a . From their release profiles, formulations F1, F2, F4, and F5 retard the release of the drug only for 4 h when as F3 and F6 retard up to 8 h. Due to the single component matrix, the prepared MDDS F1, F2, F4, and F5 resulted in faster drug release where 82.95%, 71.9%, 78.5%, and 74.7% of drug were released after 2 h and 97.2%, 84.7%, 95.6%, and 95.6% of drug were released after 4 h, respectively.
Although the single component matrix could not sustain the release of venlafaxine hydrochloride, the formulations F3 and F6 showed a lesser release rate compared to other formulations, i.e. F1, F2, F4, and F5. In case of F3 and F6, 54.9 % and 68.5% of drug were released in 2 h, and 69.2% and 85.5 % of drug were released in 4 h, and 96.3% and 99.6% release of drug in 8 h, respectively. The differences in release profile for these formulations could be attributable to failure in the formation of matrix network during dissolution due to less cohesiveness in the swollen matrix leading to shown in Figure 3c . This retardation of drug release by the optimized formulation (F8) may be due to strong synergistic interactions between polymers resulted in the formation of polyelectrolyte complex with reduced porosity.
Kinetic modeling of drug release
In vitro release data of venlafaxine HCl from the MDDS were fitted to various kinetic models to understand the order and mechanism of drug release. Here, the formulations F7, F8, F9, F11, and Venlor XR were considered as they are capable to extend the drug release as that of commercial available product and the results were shown in Table 5 . The kinetic model with the highest correlation coefficient value (r 2 ) was selected as the model that best describes the dissolution data. From the results, it is clear that the release of drug from the (F8) optimized formulation followed first-order Kinetics through Quasi-Fickian diffusion.
CONCLUSION
The MDDS of venlafaxine hydrochloride were successfully prepared using natural polymers as release retardant. FTIR studies showed that there is no much interaction between drug and polymers also with optimized formulation (F8). The DSC analyses indicated that the drug was uniformly dispersed in the chitosan and XG matrix. Different parameters such as percentage yield, flow properties, weight variation, disintegration time, drug content, and in vitro drug release were evaluated for all formulations. Based on these results, formulation (F8) was found to be most promising formulation. The release of the optimized formulation (F8) was capable of releasing drug up to 20 h and follows first-order kinetics through Quasi-Fickian diffusion. These findings suggest that the developed MDDS using chitosan, XG of venlafaxine hydrochloride could perform better than the commercially available reference product (Venlor XR), by achieving a retarding effect. Thus, the aim of this study was achieved. Hence, binary mixture of chitosan and XG could be a versatile release retardant for controlled the release of the drug. 
